Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations’); and in continuation to its letter bearing reference no. Ref. No.: WOCK/SEC/SE/2024-25/032 dated 5th August, 2024, Wockhardt has informed that the Board of Directors of the Company, at its meeting held today 9th August, 2024, have approved: 1. The Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2024. Pursuant to Regulations 30 and 33 of Listing Regulations read with Para A of Part A of Schedule III of Listing Regulations, it has enclosed the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2024 along with the Limited Review Report thereon issued by M S K C & Associates., Statutory Auditors of the Company as Annexure I. 2. Appointment of Paresh Kajrolkar, Head of Internal Audit, based on recommendations of Audit Committee, as Internal Auditor of the Company with effect from 9th August, 2024. The details required to be furnished pursuant under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure-II. The meeting of the Board of Directors commenced at 12:20 pm and concluded at 2:50 pm.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |